mole mapping managing high risk patients through imaging
play

Mole Mapping: Managing High Risk Patients through Imaging - PowerPoint PPT Presentation

Mole Mapping: Managing High Risk Patients through Imaging Disclosures Chief Medical Officer for MoleSafe USA, LLC Mole Mapping: Managing High Risk Patients through Imaging This session will focus on utilizing imaging


  1. Mole ‐ Mapping: Managing High ‐ Risk Patients through Imaging

  2. Disclosures • Chief Medical Officer for MoleSafe USA, LLC

  3. Mole ‐ Mapping: Managing High ‐ Risk Patients through Imaging • This session will focus on utilizing imaging technology for the management of patients at “high ‐ risk” for melanoma

  4. ABCD’s of Melanoma A – Asymmetry B – Border Irregularity C – Color Variegation D – Diameter great than 6 mm

  5. And E E – Evolving ‐ Size ‐ Shape ‐ Symptoms ‐ Surface Bleeding ‐ Shades of Color Abbasi,N.R.et al. Early Diagnosis of Cutaneous Melanoma.Revisiting The ABCD Criteria .JAMA. 2004;292:2771 ‐ 2776

  6. Defining a “High ‐ Risk” Patient • North America Definition • Personal History of Melanoma • Family History of Melanoma • Dysplastic Nevi • Many Nevi • Fair skin, inability to tan Watts CG, Dieng M, Morton RL, et al. Clinical practice guidelines for identification, screening and follow ‐ up of individuals at high risk of primary cutaneous melanoma: a systematic review. British Journal of Dermatology. 2015: 33 ‐ 47

  7. Melanoma Statistics • Increase in incidents rates • It is estimated that the number of new melanoma cases diagnosed in 2019 will increase 7.7% • Most new melanomas are de novo • How can we spot them? American Cancer Society – Cancer Facts & Figures 2019 A meta ‐ analysis of nevus ‐ associated melanoma: Prevalence and practical implications Pampena, Riccardo et al. Journal of the American Academy of Dermatology, Volume 77, Issue 5, 938 ‐ 945.e4

  8. A recent study published in the JAAD shows that there is general agreement among Pigmented Lesion Experts recommending Total Body Photography and Dermoscopic Imaging for “high ‐ risk” patients. Total Body Photography Serial Digital Dermoscopic Imaging Recommendation #1: Total body Strongly Agree: 55% photography is recommended for Strongly Agree: 91% Agree: 27% patients with familial atypical multiple Agree: 0% Recommendation #1: Serial digital Neither Agree nor Disagree: mole melanoma syndrome (FAMMM Neither Agree nor Disagree: 9% dermoscopic imaging is recommended 0% Syndrome, aka dysplastic nevus Disagree: 0% for montioring "ugly duckling" nevi with Disagree: 0% syndrome) Strongly Disagree: 0% equivocal dermoscopic features Strongly Disagree: 18% Recommendation #2: Total body photography is recommended in adults with > than 50 nevi that have one or more of the following: (1) a personal history of multiple cutaneous melanomas; (2) a Recommendation #2: Serial digital Strongly Agree: 27% personal history of an amelanotic Strongly Agree: 64% dermoscopic imaging is recommended in Agree: 55% melanoma; multiple pink nevi, multiple Agree: 36% patiets with a large or growing lentigo ‐ Neither Agree no Disagree: clinically atypical nevi, and/or; (3) a Neither Agree no Disagree: 0% like lesion that lack diagnostic 18% genetic syndrome that predisposes to the Disagree: 0% dermoscopic features with a plan to re ‐ Disagree: 9% development of cutaneous melanoma. Strongly Disagree: 0% evaluate at a three to six ‐ month interval Strongly Disagree: 0% Waldman RA, Grant ‐ Kels JM, Curiel CN, Curtis J, Rodriguez SG, Hu S, Kerr P, Marghoob A, Markowitz O, Pellacani G, Rabinovitz H, Rao B, Scope A, Stein JA, Swetter SM, Consensus Recommendations for the Use of Non ‐ Invasive Melanoma Detection Techniques Based on Results of an International DELPHI Process, Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/j.jaad.2019.09.046.

  9. A recent study published in the JAAD shows that there is general agreement among Pigmented Lesion Experts recommending Total Body Photography and Dermoscopic Imaging for “high ‐ risk” patients. Waldman RA, Grant ‐ Kels JM, Curiel CN, Curtis J, Rodriguez SG, Hu S, Kerr P, Marghoob A, Markowitz O, Pellacani G, Rabinovitz H, Rao B, Scope A, Stein JA, Swetter SM, Consensus Recommendations for the Use of Non ‐ Invasive Melanoma Detection Techniques Based on Results of an International DELPHI Process, Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/j.jaad.2019.09.046.

  10. What is Mole ‐ Mapping? • Combining multiple imaging techniques and clinical follow ‐ up • Total Body Photography • Clinical Imaging • Dermoscopic Imaging 1 + 1 = 3

  11. Total Body Photography (TBP)

  12. TBP – Photographic Medical Record Creating a benchmark, similar to an EKG or x ‐ ray

  13. Incidence of New and Changed Nevi and Melanomas Detected Using Baseline Images and Dermoscopy in Patients at High Risk for Melanoma • The use of baseline photography and dermoscopy was associated with low biopsy rates and early detection of melanomas. Only 3 nevi were biopsied for every melanoma. • This compares to benign ‐ malignant ratios of 12:1 for dermatologists and 30:1 for general physicians. Jeremy P. Banky, MBBS; John W. Kelly, MDBS; Arch Dermatol. 2005;141:998-1006.

  14. TBP – Identifying New Lesions

  15. TBP – Identifying Changing Lesions

  16. Underlying Rationale of using TBP ‐ Stable lesions are biologically indolent (senescent) ‐ New/Changing lesions are biologically relevant & may represent: ‐ Melanoma ‐ Melanoma Precursor Courtesy of Dr. Marghoob & Dr. Rabinovitz

  17. TS1 < 1 ‐ 3% new or changed lesions will be melanoma (clinical) Study Year # pts. # lesions Nevi/ # # %MM/ patient changed melanoma changed Schiffner 2003 145 272 1.9 95 0 0.0 Bauer 2005 196 2015 10.3 128 2 1.6 Robinson 2004 100 3482 34.8 193 4 2.1 Banky 2005 309 573 18 3.1 Kittler 2000 202 1862 9.2 75 8 10.7 Menzies 2001 245 318 1.3 61 7 11.5 Hasenssle 2004 212 2939 13.9 112 15 13.4 Altamura 2008 1859 2602 1.4 487 81 16.6 Courtesy of Dr. Marghoob & Dr. Rabinovitz

  18. Slide 18 TS1 Taylor Sheridan, 10/11/2019

  19. Patients who benefit from Total Body Photography • Personal/Family History of melanoma • Atypical/Dysplastic Nevi Syndrome • Multiple Nevi of different size, shape, and color • Patient’s with high anxiety of developing melanoma

  20. Clinical/Dermoscopic Imaging

  21. How good are skin cancer specialists at diagnosing melanoma based on visual examination alone? • Sensitivity = 70% • Specificity = 75% • NNT (benign: malignant ratio) = 12-15 Bafounta. Arch Dermatol 2001;137:1343 Marks. JAAD;1997;36:599 Hansen. JAAD 2009;61:599 Vestergaard. BJD 2008;159:669 Carli , BJD;2004;150:687 Courtesy of Dr. Marghoob & Dr. Rabinovitz

  22. Diagnostic accuracy of melanoma may be improved with dermoscopy Pehamberger et al. 1993: diagnostic accuracy of 46 ‐ 54% (clinical) increasing to 62 ‐ 91% (dermoscopy)

  23. How good are skin cancer specialists at diagnosing melanoma with aid of dermoscopy? • Sensitivity = 90% • Specificity = 86% • NNT (benign:malignant ratio) = 4-7 Vestergaard. BJD 2008;159:669 Bafounta, Arch Dermatol 2001;137:1343 Hansen. JAAD 2009;61:599 Carli , BJD;2004;150:687 Courtesy of Dr. Marghoob & Dr. Rabinovitz

  24. Spectrum of Melanocytic Lesions Nevi Malignant Melanoma

  25. Clinical Exam There are only a few clinical features which separate melanoma from nevi. Nevi Malignant Melanoma Clinically Uncertain Lesions Lesions in the overlapping area often require a biopsy for diagnosis.

  26. Dermoscopic Exam With dermoscopy there are dermoscopic features that correlate to benign or malignant patterns, thereby improving accuracy over clinical visual inspection Malignant Nevi Melanoma Benign Patterns Malignant Patterns Intrinsic Limitation of Dermoscopy: Uncertain Patterns

  27. Sometimes a dermatoscope isn’t enough • Powerful tool to aid the diagnosis of early melanomas • High ‐ risk patients need more than a “point in time” evaluation

  28. Sometimes a dermatoscope isn’t enough • How can you spot change without reference images?

  29. Short Term Surveillance Image a suspicious melanocytic lesion that does not satisfy the classic dermoscopic criteria for the diagnosis of melanoma. The lesion is then re ‐ imaged at 3 month intervals. If a change is noted, the lesion is biopsied. It is believed that if a lesion is malignant, there will be a change within this time period without a significant risk to the patient.

  30. The Value of Serial Digital Dermoscopic Imaging (SDDI)

  31. Why use Mole Mapping? • For Providers • Increased Sensitivity & Specificity • Reduced Benign ‐ to ‐ Malignant Ratio • Time Restrictions • For Patients • Earlier Diagnosis • No more “is that all?” • Reduce Patient Anxiety

  32. How to incorporate Mole Mapping into your Practice There are many options: 1. The use of Electronic Medical Records 2. Outsourcing to imaging clinics

  33. Thank You!

Recommend


More recommend